Actinium Pharmaceuticals Inc (ATNM)

[stockguard]

From December 8th at Benzinga Global Small Cap Conference Day 1 Recap:
Actinium Pharmaceuticals Says SIERRA Trial Has Demonstrated All Patients Receiving Therapeutic Dose Of Iomab-B Have Been Able To Go On to Bone Marrow Transplant
Actinium Pharmaceuticals Says Estimates ~176K Patients/Year Diagnosed With Blood Cancers Treatable With Bone Marrow Transplant But Only 23K Transplants Performed In 2018, Says Looking To Address Access Gap With Iomab-B
Actinium Pharmaceuticals CFO Steve O'Loughlin Notes Co.'s ARCs Enable Targeted Radiotherapy Directly To Cancer Cells; Says Has Over 130 Patents That Protect Candidates Through 2037 And Beyond
Actinium Pharmaceuticals CFO Steve O'Loughlin Highlights Co. Balance Sheet; ~$48M In Cash, Which Can Fund Operations Through 2021
Actinium Pharmaceuticals CFO Steve O'Loughlin Says Co. Led By Iomab-B, Which Is In Phase 3 SIERRA Trial; Has Also Expanded Into Bone Marrow, Transplant CAR-T And Gene Therapy
Actinium Reports 67% Overall Response Rate In First Cohort In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML At ASH 2020